Jacobio Pharma receives breakthrough therapy designation for glecirasib

Jacobio Pharma received breakthrough therapy designation (BTD) for glecirasib to treat pancreatic cancer patients with the KRAS G12C mutation.

Aug 8, 2023 - 20:00
Jacobio Pharma receives breakthrough therapy designation for glecirasib
Jacobio Pharma received breakthrough therapy designation (BTD) for glecirasib to treat pancreatic cancer patients with the KRAS G12C mutation.

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow